The EFSA panel assessed how much caffeine people can take from all dietary sources without safety concerns. For healthy adults who are not pregnant, up to 400 mg a day and up to 200 mg at once raised no concern, including within 2 hours of intense exercise. The panel set 200 mg a day for pregnant women and said the evidence was too thin to set a figure for children and adolescents.
The European Commission asked the European Food Safety Authority how much caffeine people can take from all food sources without safety concerns, and whether energy drink ingredients, alcohol, p-synephrine or intense exercise change that answer. The Panel covered healthy adults plus pregnant women, breastfeeding women, children and adolescents.
This is a scientific opinion from the Panel on Dietetic Products, Nutrition and Allergies, adopted April 2015. It is a risk assessment, not new research. The Panel reviewed earlier safety assessments by other bodies, then human evidence on cardiovascular outcomes, hydration, sleep, anxiety, behavior and birth weight. Intervention trials and prospective cohorts were preferred over case-control and cross-sectional studies, and case reports were excluded. Intake came from the EFSA Comprehensive European Food Consumption Database: 39 surveys, 22 countries, 66,531 participants, plus a separate EFSA report on energy drinks.
The Panel set these levels of no safety concern:
Single doses of 100 mg, about 1.4 mg per kg, may lengthen the time it takes to fall asleep in some people, particularly near bedtime. Taurine and D-glucurono-gamma-lactone at typical energy drink levels, and alcohol up to about 0.65 g per kg, would not change the safety of a 200 mg caffeine dose. On p-synephrine the Panel drew no conclusion: the human research is inadequate. In 7 of 13 countries the 95th percentile of daily adult intake exceeded 400 mg, with 6 to 33 percent of adults over that level, mostly from coffee. About 6 percent exceed 200 mg in a single energy drink session.
The Panel flags several gaps. For children and adolescents it says plainly the evidence is not enough to set a safe intake, and uncertainty remains about long-term effects on anxiety and behavior. Its figure is borrowed from adult data because caffeine clearance in children is at least as fast. The intake surveys differ in method and year, so the Panel warns against direct country comparisons. It holds no data on caffeine supplements, and little on pregnant or lactating women. The opinion excludes people with a disease condition, genetic vulnerability, medicines, drugs of abuse and heavy alcohol use. Most trials behind the conclusions used caffeine supplements, not coffee or tea. The document is copyrighted by the European Food Safety Authority, 2015. No conflict of interest or funding declaration appears in the text.
This is a safety ceiling, not a recommendation to consume anything. The numbers mark where harm has not been shown in healthy people, a different claim from saying caffeine is beneficial. The report declines to assess benefit. Two points deserve care: the children and adolescent figure is an assumption carried over from adults, not a finding, and p-synephrine is left open. Anyone with a health condition or on medication is outside its scope.
That depends on the specific medication and formula. A few, like blood thinners with CurQLife or blood pressure medication with MaxiNOs, are worth a direct conversation with your doctor first. Check each formula's own FAQ section for specifics, or ask your health coach.
No, and we'd rather be upfront about it. Bacopa, the plant in BacoZest, has published human studies, though they used other bacopa extracts. OptiNOs and MaxiNOs each have human studies sponsored by their maker, Laila Nutraceuticals, which haven't been published in a journal. CurQLife's research is still early, from lab and animal studies, and we label it that way.
It depends on what you're building your routine around. BacoZest is built around bacopa, which is studied for memory.* OptiNOs supports strength and muscular endurance alongside resistance training.* MaxiNOs was studied for healthy blood vessel function.* CurQLife's research is still at the lab stage. Your health coach can help you pick a starting point.
All four are built around plant extracts. OptiNOs was reported as well tolerated in its human study, and published bacopa studies reported no serious side effects. CurQLife's safety data so far comes from lab and animal testing. Check with your doctor first if you're pregnant, nursing, on medication, or managing a health condition.
Because the patented ingredients behind our four formulas went through dedicated research, and research costs real money. A generic curcumin or bacopa supplement hasn't been tested in the form you get from us. You're paying for an ingredient with research behind it, not just a label.
Generic ingredients often haven't been studied in the specific form you're buying. Our four core formulas use patented ingredients, and we show you the research behind each one, including where it's still early.
It depends on the formula. In its study, MaxiNOs blood vessel response was higher than placebo 2 to 3 hours after the first dose.* OptiNOs and bacopa were studied over 6 and 12 weeks of daily use, so give them time. CurQLife is meant to be taken daily.
Yes. BacoZest, OptiNOs, MaxiNOs, and CurQLife are built for different goals, and none of them contain stimulants. They haven't been studied together, so ask your health coach how to fit them into your routine.
